Paris, August 24th, 2010 – BioAlliance Pharma SA (Euronext Paris – BIO), a company
dedicated to the supportive care and treatment of cancer patients, today announces the
launch in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of
oropharyngeal candidiasis (OPC) in adults by its commercial partner, Strativa
Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc.
With a US FDA approval in April 2010, BioAlliance Pharma is the first small medium-sized
innovative French company to have access to the American market, the largest worldwide
Oravig® is already available on the US market. The national sales force meeting of Strativa is
being held this week in the United States to prepare the promotion of the product to the
«The US launch of Oravig® is the ultimate step of a process that confirms our expertise in
development and registration of products at the international level. It represents a major
achievement that will generate significant revenues for BioAlliance Pharma», declares
Dominique Costantini, its CEO. « We are very confident in Strativa sales team’s commitment
and know-how to ensure Oravig® success in the US, a product presenting a strong synergy
with the product portfolio already commercialized by our US partner».
About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and
radiotherapy-induced complications and opportunistic infections in immunocompromised patients –
BioAlliance conceives and develops innovative products, especially in the hospital setting and for
orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition
is to become a leading player in these fields by coupling innovation to patient needs. The company’s
teams have the key competencies required to identify, develop and register drugs in Europe and the
USA; the products’ commercialization rights are licensed to international commercial partners invested
in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches
help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
Loramyc®(Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European
countries, in Korea and in the United States
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced
nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEP® (Invasive melanoma): Phase I
Clonidine Lauriad® (Mucositis): Phase II
Doxorubicine Transdrug® (Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
About Strativa Pharmaceuticals
Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par
Pharmaceutical Companies, Inc. (NYSE:PRX), excels at finding, enhancing, and bringing to market
drugs that make a meaningful difference to patients. For more information about Strativa, visit
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company. Through its
wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals,
it develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative
proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and
its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA
is providing this communication as of this date and does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of
BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the
AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59